Pulse's $4M seed bet on India's medical equipment manufacturing gap

Pulse, a Bengaluru-based medical equipment startup founded in 2025, closed a $4M seed round led by 3one4 Capital in February 2026, with participation from Incubate Fund Asia, Stride Ventures, and angel investors including founders of Blackbuck and Agrizy. The round signals investor conviction in a full-stack, asset-light model: Pulse partners with Indian MSMEs to manufacture medical equipment while handling design, quality systems, and regulatory compliance itself. The startup currently works with nearly 20 MSMEs across Delhi NCR, Jammu, Gujarat, Kolkata, and Mumbai, manufacturing products such as blood tubing sets and anaesthesia machines. The capital will fund an R&D hub, product development, regulatory approvals, and expansion of the distribution network across India and select export markets.

The timing aligns with structural tailwinds in Indian medical devices. India’s medical devices industry is projected to reach $50.1B by 2030 from $15.2B in 2025, representing a 26.9% compound annual growth rate. Despite this projected growth, India currently imports nearly 80% of its medical equipment, creating a localized manufacturing and supply-chain opportunity. Pulse’s model targets mid-tier hospitals with 50–200 beds initially, focusing on critical care and renal care products, with plans to expand into larger hospital chains and adjacent medical specialties over time. The bet appears positioned between pure marketplace plays and vertically integrated manufacturing—outsourcing production to MSMEs rather than building owned factories.

The open question is whether Pulse can achieve regulatory compliance and quality certification at scale across a fragmented MSME supplier base while maintaining cost advantages over incumbent importers. Details on the startup’s current revenue, unit economics, or customer acquisition costs were not disclosed in early reporting. Also worth watching: how the export ambition unfolds, given that medical device exports require navigating multiple regulatory regimes. The round does not clarify whether Pulse plans to remain asset-light or eventually own manufacturing capacity as it scales.